2
Specific identification of chronic lung disease in premature babies
mehr
Storys zum Thema Krankheit
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Pluripotency or differentiation - that is the question
mehrEANS-Adhoc: Marinomed Biotech AG announces top line results of the Phase III study for Budesolv
issuer: Marinomed Biotech AG Veterinärplatz 1 A-1210 Wien phone: 0043250774460 FAX: 0043250774493 mail: office@marinomed.com WWW: www.marinomed.com ISIN: ATMARINOMED6, AT0000A1WD52 indexes: stockmarkets: Wien language: English ...
mehr- 2
CD30 - from witness to culprit
mehr Technische Universität München
ERC Grants awarded to TUM researchers
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/detail/article/35313/ NEWS RELEASE Cutting-edge research from robotics to simulated flows ERC Advanced and Proof of Concept Grants awarded to TUM researchers The European Research Council (ERC) will fund three projects ...
mehrMundipharma EDO GmbH: US FDA Grants Orphan Drug Designation for Tinostamustine in Very Rare Blood Cancer
Basel, Switzerland (ots/PRNewswire) - FOR EX-US MEDICAL AND TRADE MEDIA ONLY - T-cell prolymphocytic leukaemia is an extremely rare and aggressive T-cell leukaemia, with very limited effective treatment options1,2 - Tinostamustine is in very early phase clinical trials to investigate it as a potential future ...
mehrSysmex Inostics' OncoBEAM(TM) demonstrates clinical validity and superior performance versus pan-cancer NGS for blood-based mutation detection for hepatocellular carcinoma
Hamburg, Germany (ots) - Data recently published in Clinical Cancer Research (http://ots.de/0ZGZkf) the advantages of using an ultra-high sensitivity test for detection of mutations which may predict therapeutic efficacy for hepatocellular carcinoma (HCC). Sysmex Inostics' OncoBEAM technology, a highly clinically ...
mehr
Vorherige234567891011